Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

  1. Godman, B.
  2. Malmström, R.E.
  3. Diogene, E.
  4. Jayathissa, S.
  5. McTaggart, S.
  6. Cars, T.
  7. Alvarez-Madrazo, S.
  8. Baumgärtel, C.
  9. Brzezinska, A.
  10. Bucsics, A.
  11. Campbell, S.
  12. Eriksson, I.
  13. Finlayson, A.
  14. Fürst, J.
  15. Garuoliene, K.
  16. Gutiérrez-Ibarluzea, I.
  17. Hviding, K.
  18. Herholz, H.
  19. Joppi, R.
  20. Kalaba, M.
  21. Laius, O.
  22. Malinowska, K.
  23. Pedersen, H.B.
  24. Markovic-Pekovic, V.
  25. Piessnegger, J.
  26. Selke, G.
  27. Sermet, C.
  28. Spillane, S.
  29. Tomek, D.
  30. Vončina, L.
  31. Vlahović-Palčevski, V.
  32. Wale, J.
  33. Wladysiuk, M.
  34. van Woerkom, M.
  35. Zara, C.
  36. Gustafsson, L.L.
  37. Show all authors +
Journal:
Frontiers in Pharmacology

ISSN: 1663-9812

Year of publication: 2014

Volume: 5 JUN

Type: Review

DOI: 10.3389/FPHAR.2014.00109 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus